Cargando…
The Effect of the Sodium—Glucose Cotransporter Inhibitor on Cognition and Metabolic Parameters in a Rat Model of Sporadic Alzheimer’s Disease
Type 2 diabetes mellitus increases the risk of sporadic Alzheimer’s disease (sAD), and antidiabetic drugs, including the sodium–glucose cotransporter inhibitors (SGLTI), are being studied as possible sAD therapy. We have explored whether the SGLTI phloridzin may influence metabolic and cognitive par...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10135566/ https://www.ncbi.nlm.nih.gov/pubmed/37189641 http://dx.doi.org/10.3390/biomedicines11041025 |
_version_ | 1785032010183475200 |
---|---|
author | Osmanović Barilar, Jelena Babić Perhoč, Ana Knezović, Ana Homolak, Jan Virag, Davor Šalković-Petrišić, Melita |
author_facet | Osmanović Barilar, Jelena Babić Perhoč, Ana Knezović, Ana Homolak, Jan Virag, Davor Šalković-Petrišić, Melita |
author_sort | Osmanović Barilar, Jelena |
collection | PubMed |
description | Type 2 diabetes mellitus increases the risk of sporadic Alzheimer’s disease (sAD), and antidiabetic drugs, including the sodium–glucose cotransporter inhibitors (SGLTI), are being studied as possible sAD therapy. We have explored whether the SGLTI phloridzin may influence metabolic and cognitive parameters in a rat model of sAD. Adult male Wistar rats were randomized to a control (CTR), an sAD-model group induced by intracerebroventricular streptozotocin (STZ-icv; 3 mg/kg), a CTR+SGLTI, or an STZ-icv+SGLTI group. Two-month-long oral (gavage) SGLTI treatment (10 mg/kg) was initiated 1 month after STZ-icv and cognitive performance tested prior to sacrifice. SGLTI treatment significantly decreased plasma glucose levels only in the CTR group and failed to correct STZ-icv-induced cognitive deficit. In both the CTR and STZ-icv groups, SGLTI treatment diminished weight gain, decreased amyloid beta (Aβ) 1-42 in duodenum, and decreased the plasma levels of total glucagon-like peptide 1 (GLP-1), while the levels of active GLP-1, as well as both total and active glucose-dependent insulinotropic polypeptide, remained unchanged, compared to their respective controls. The increment in GLP-1 levels in the cerebrospinal fluid and its effect on Aβ 1-42 in duodenum could be one of the molecular mechanisms by which SGLTIs indirectly induce pleiotropic beneficial effects. |
format | Online Article Text |
id | pubmed-10135566 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-101355662023-04-28 The Effect of the Sodium—Glucose Cotransporter Inhibitor on Cognition and Metabolic Parameters in a Rat Model of Sporadic Alzheimer’s Disease Osmanović Barilar, Jelena Babić Perhoč, Ana Knezović, Ana Homolak, Jan Virag, Davor Šalković-Petrišić, Melita Biomedicines Article Type 2 diabetes mellitus increases the risk of sporadic Alzheimer’s disease (sAD), and antidiabetic drugs, including the sodium–glucose cotransporter inhibitors (SGLTI), are being studied as possible sAD therapy. We have explored whether the SGLTI phloridzin may influence metabolic and cognitive parameters in a rat model of sAD. Adult male Wistar rats were randomized to a control (CTR), an sAD-model group induced by intracerebroventricular streptozotocin (STZ-icv; 3 mg/kg), a CTR+SGLTI, or an STZ-icv+SGLTI group. Two-month-long oral (gavage) SGLTI treatment (10 mg/kg) was initiated 1 month after STZ-icv and cognitive performance tested prior to sacrifice. SGLTI treatment significantly decreased plasma glucose levels only in the CTR group and failed to correct STZ-icv-induced cognitive deficit. In both the CTR and STZ-icv groups, SGLTI treatment diminished weight gain, decreased amyloid beta (Aβ) 1-42 in duodenum, and decreased the plasma levels of total glucagon-like peptide 1 (GLP-1), while the levels of active GLP-1, as well as both total and active glucose-dependent insulinotropic polypeptide, remained unchanged, compared to their respective controls. The increment in GLP-1 levels in the cerebrospinal fluid and its effect on Aβ 1-42 in duodenum could be one of the molecular mechanisms by which SGLTIs indirectly induce pleiotropic beneficial effects. MDPI 2023-03-27 /pmc/articles/PMC10135566/ /pubmed/37189641 http://dx.doi.org/10.3390/biomedicines11041025 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Osmanović Barilar, Jelena Babić Perhoč, Ana Knezović, Ana Homolak, Jan Virag, Davor Šalković-Petrišić, Melita The Effect of the Sodium—Glucose Cotransporter Inhibitor on Cognition and Metabolic Parameters in a Rat Model of Sporadic Alzheimer’s Disease |
title | The Effect of the Sodium—Glucose Cotransporter Inhibitor on Cognition and Metabolic Parameters in a Rat Model of Sporadic Alzheimer’s Disease |
title_full | The Effect of the Sodium—Glucose Cotransporter Inhibitor on Cognition and Metabolic Parameters in a Rat Model of Sporadic Alzheimer’s Disease |
title_fullStr | The Effect of the Sodium—Glucose Cotransporter Inhibitor on Cognition and Metabolic Parameters in a Rat Model of Sporadic Alzheimer’s Disease |
title_full_unstemmed | The Effect of the Sodium—Glucose Cotransporter Inhibitor on Cognition and Metabolic Parameters in a Rat Model of Sporadic Alzheimer’s Disease |
title_short | The Effect of the Sodium—Glucose Cotransporter Inhibitor on Cognition and Metabolic Parameters in a Rat Model of Sporadic Alzheimer’s Disease |
title_sort | effect of the sodium—glucose cotransporter inhibitor on cognition and metabolic parameters in a rat model of sporadic alzheimer’s disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10135566/ https://www.ncbi.nlm.nih.gov/pubmed/37189641 http://dx.doi.org/10.3390/biomedicines11041025 |
work_keys_str_mv | AT osmanovicbarilarjelena theeffectofthesodiumglucosecotransporterinhibitoroncognitionandmetabolicparametersinaratmodelofsporadicalzheimersdisease AT babicperhocana theeffectofthesodiumglucosecotransporterinhibitoroncognitionandmetabolicparametersinaratmodelofsporadicalzheimersdisease AT knezovicana theeffectofthesodiumglucosecotransporterinhibitoroncognitionandmetabolicparametersinaratmodelofsporadicalzheimersdisease AT homolakjan theeffectofthesodiumglucosecotransporterinhibitoroncognitionandmetabolicparametersinaratmodelofsporadicalzheimersdisease AT viragdavor theeffectofthesodiumglucosecotransporterinhibitoroncognitionandmetabolicparametersinaratmodelofsporadicalzheimersdisease AT salkovicpetrisicmelita theeffectofthesodiumglucosecotransporterinhibitoroncognitionandmetabolicparametersinaratmodelofsporadicalzheimersdisease AT osmanovicbarilarjelena effectofthesodiumglucosecotransporterinhibitoroncognitionandmetabolicparametersinaratmodelofsporadicalzheimersdisease AT babicperhocana effectofthesodiumglucosecotransporterinhibitoroncognitionandmetabolicparametersinaratmodelofsporadicalzheimersdisease AT knezovicana effectofthesodiumglucosecotransporterinhibitoroncognitionandmetabolicparametersinaratmodelofsporadicalzheimersdisease AT homolakjan effectofthesodiumglucosecotransporterinhibitoroncognitionandmetabolicparametersinaratmodelofsporadicalzheimersdisease AT viragdavor effectofthesodiumglucosecotransporterinhibitoroncognitionandmetabolicparametersinaratmodelofsporadicalzheimersdisease AT salkovicpetrisicmelita effectofthesodiumglucosecotransporterinhibitoroncognitionandmetabolicparametersinaratmodelofsporadicalzheimersdisease |